¹⁸ F‐PI‐2620 tau‐PET in corticobasal syndrome (ActiGliA cohort)

The pathology of Corticobasal syndrome (CBS) is characterized by 4‐repeat (4R)‐tau aggregation in Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) in ∼50%, or by (3/4R)‐tau aggregation in Alzheimer’s disease (AD) in ∼25% of patients. The second generation tau‐PET ligand 18F‐PI2620 showed high affinity to 3/4R‐tau in AD and also revealed affinity to 4R‐tau pathology. The aim of this study was to investigate 18F‐PI2620 in patients with CBS that are part of the interdisciplinary AD study “Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer‘s Disease (ActiGliA)”.